Considering all the above findings, we hence hypothesized in the current study that HDAC inhibitor ITF2357 was likely to regulate the chemoresistance of mutant (mut)-KRAS NSCLC to Pem, with the involvement of the miR-130a-3p/HDAC2/Rad51 axis. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.